Arvinas, Inc. (ARVN)

Market Cap	719.49M
Revenue (ttm)	372.80M
Net Income (ttm)	-72.60M
Shares Out	73.42M
EPS (ttm)	-1.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,051,444
Open	9.50
Previous Close	9.46
Day's Range	9.40 - 9.95
52-Week Range	5.90 - 29.61
Beta	2.39
Analysts	Buy
Price Target	17.70 (+80.61%)
Earnings Date	Oct 29, 2025

About ARVN

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 27, 2018
• Employees: 430
• Stock Exchange: NASDAQ
• Ticker Symbol: ARVN
• Website: https://www.arvinas.com

Financial Performance

In 2024, Arvinas's revenue was $263.40 million, an increase of 235.54% compared to the previous year's $78.50 million. Losses were -$198.90 million, -45.85% less than in 2023.

Analyst Summary

According to 23 analysts, the average rating for ARVN stock is "Buy." The 12-month stock price target is $17.7, which is an increase of 80.61% from the latest price.

Price Target

$17.7

(80.61% upside)

Analyst Consensus: Buy